DoxorubicinAntibiotics, AntineoplasticAnthracyclinesNaphthacenesAntineoplastic AgentsDaunorubicinRazoxaneAclarubicinNogalamycinCarubicinLeukemia P388Antineoplastic Combined Chemotherapy ProtocolsIdarubicinStreptomycesMenogarilEpirubicinAnti-Bacterial AgentsBreast NeoplasmsCyclophosphamideAntibiotic ProphylaxisVincristineDrug Resistance, NeoplasmLeukemia L1210Drug Resistance, MultipleCardiotoxinsBridged CompoundsP-GlycoproteinDose-Response Relationship, DrugAntineoplastic Agents, PhytogenicDrug Screening Assays, AntitumorPaclitaxelTaxoidsDrug ResistanceTreatment OutcomeCell Line, TumorHeart DiseasesIntercalating AgentsTumor Cells, CulturedNeoplasmsMicrobial Sensitivity TestsDrug Administration ScheduleDrug SynergismCardiomyopathiesVinblastineExtravasation of Diagnostic and Therapeutic MaterialsCell SurvivalMolecular StructureApoptosisDrug CarriersLiposomesFluorouracilEtoposideMitoxantroneCisplatinDNA Topoisomerases, Type IIDrug Resistance, BacterialDrug Resistance, MicrobialTime FactorsFermentationHeartAntineoplastic Agents, AlkylatingCytarabineVerapamilDisease-Free SurvivalEpothilonesAminoglycosidesMethotrexateBacteriaSurvival AnalysisTopoisomerase II InhibitorsInfusions, IntravenousAnthraquinonesChemotherapy, AdjuvantAntimetabolites, AntineoplasticNeoplasm MetastasisDrug Evaluation, PreclinicalChemistryMagnetic Resonance SpectroscopyMacrolidesPolyethylene GlycolsChemical PhenomenaDrug EvaluationMitomycinStructure-Activity RelationshipBacterial InfectionsGlycosidesPhysicochemical PhenomenaBleomycinHL-60 CellsDeoxycytidineChemistry, PhysicalDNA DamageMicromonosporaHydrazonesNeoplasm TransplantationCombined Modality TherapyGentamicinsDrug InteractionsPrednisoneDrug Utilization